Clinical Trial Update: A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) [Phase 3]

View source ↗

Summary

This Phase 3 trial update reports results for deficient mismatch repair/microsatellite instability-high metastatic colorectal cancer comparing nivolumab alone, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Investigator's Choice Chemotherapy
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Metastatic Colorectal Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-09-22